Investors

BXQ-350 provides a value proposition that is possibly unprecedented

in how it may address significant unmet medical need across these patient populations suffering from devastating malignant disease.

BXQ-350 is a Phase 2a clinical-stage, novel, first-in-class biologic

that has a unique mechanism of action, sphingolipid metabolism modulation which favorably activates multiple enzymes, thereby providing the potential for direct anti-tumor efficacy across a variety of advanced solid tumors and neurological disease.

Metastatic Colorectal Cancer patients continue to have an inferior prognosis despite the use of Standard of Care (SOC) (FOLFOX + bevacizumab). Very few therapies have been approved in first line mCRC in the past decade

In mCRC, mPFS (median Progression Free Survival) averages 9-10 months and mOS (median Overall Survival) is 22-24 months with SOC (FOLFOX + bevacizumab).

FOLFOX is a chemotherapeutic regimen containing Oxaliplatin which is commonly associated with major dose-limiting toxicity (DLT) resulting in reduction in dose, skipping a dose or removal of Oxaliplatin in these patients.

2nd most

Colorectal cancer is the second-leading cause of cancer-related deaths in the US (numbers for men and women combined) with 55,000 deaths estimated for 2026

159k

Estimated number of colorectal cases for 2026

15%

Five-year survival for mCRC

25%

25% of CRC patients present at Stage 4 and 25% of patients with earlier stage diagnosis progress to Stage 4

1st

Colorectal cancer (CRC) mortality increased, by 1.1% per year since 2005, advancing it to be the most common cause of cancer death in men under 50 and 2nd most common cause for women under 50

*SOURCES: Colorectal Cancer — Cancer Stat Facts and Colorectal Cancer Statistics | How Common Is Colorectal Cancer? | American Cancer Society

Pipeline in a product

BXQ-350 is the first in a new class of therapies

that has the potential to address unmet medical needs in terms of anti-tumor efficacy but also in terms of anti-neuropathy effect

Early efficacy data re: anti-tumor effects

In an open‑label Phase 1b/2a study in metastatic colorectal cancer, BXQ‑350 combined with FOLFOX plus bevacizumab achieved efficacy outcomes at or above those typically reported with standard of care alone, despite a study population enriched with poor‑prognosis patients—highlighting its potential to deliver meaningful benefit in the first‑line metastatic setting.

Safety + tolerability

BXQ-350 has been well tolerated across more than six dose levels, with a favorable safety profile observed in both monotherapy and combination settings, including chemotherapy and radiation, across adult and pediatric patients. With more than 2,000 patient doses administered—including patients whose cancers were in remission—the extensive clinical safety dataset is further supported by preclinical data indicating the feasibility of additional routes of administration.

Increased Oxaliplatin Dosing

In the open label phase 1b/2a study, patients receiving BXQ-350 combined with FOLFOX and bevacizumab attained higher than expected cumulative oxaliplatin dosing with fewer dose reductions, interruptions, or early terminations. Beyond quality‑of‑life benefits, higher cumulative oxaliplatin exposure may contribute to improved treatment outcomes.

Non-cancer indications

While BXQ-350 was developed to target solid tumors specifically, early efficacy in neurological disease has emerged.

Addressing an unmet medical need

BXQ-350 has potentially unprecedented anti-tumor and anti-neurological disease effects that show promise in treating cancer patients whose options for new therapies have historically been limited.

Learn More

Resources

Find case studies, abstracts, and more about the potential breakthroughs we’re pursuing

View All